Pàgina inicial > Resultats de la cerca: Eculizumab
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
13 p, 1.8 MB The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment / Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ; Dixon, B.P. (Renal Section. Department of Pediatrics. University of Colorado School of Medicine) ; Kim, S.H. (Department of Pediatrics. Pusan National University Children's Hospital) ; Kapur, G. (Faculty of Pediatric Sciences. Central Michigan University. Mount Pleasant) ; Mauch, T. (Department of Nephrology and Hypertension. Division of Pediatrics. University of Utah) ; Ortiz, S. (Clinical and Non-Clinical Pharmacology. Alexion Pharmaceuticals Inc.) ; Vallee, M. (Biostatistics. Alexion Pharmaceuticals Inc.) ; Denker, A.E. (Clinical Development. Alexion Pharmaceuticals Inc.) ; Kang, H.G. (Division of Pediatric Nephrology. Department of Pediatrics. Seoul National University College of Medicine) ; Greenbaum, L.A. (Division of Pediatric Nephrology. Emory University School of Medicine and Children's Healthcare of Atlanta) ; Lovell, H. ; Muff-Luett, M. ; Malone, K. ; Adeagbo, O. ; Wilkerson, A. ; Fraga Rodríguez, Gloria María (Institut d'Investigació Biomèdica Sant Pau) ; Sarri, S. ; Cheong, H.I. ; Ahn, Y.H. ; Han, K.H.
Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2-3 weeks to every 4-8 weeks depending on bodyweight. Here, we evaluated the efficacy and safety of ravulizumab in complement inhibitor-naïve children (under 18 years) with atypical hemolytic uremic syndrome. [...]
2021 - 10.1016/j.kint.2020.10.046
Kidney International, Vol. 100 Núm. 1 (july 2021) , p. 225-237  
Registre complet - Creative Commons
2.
11 p, 286.2 KB Long-term safety and efficacy of eculizumab in generalized myasthenia gravis / Muppidi, Srikanth (Stanford University School of Medicine) ; Utsugisawa, Kimiaki (Hanamaki General Hospital) ; Benatar, Michael (University of Miami Miller School of Medicine) ; Murai, Hiroyuki (International University of Health and Welfare) ; Barohn, Richard J. (University of Kansas Medical Center) ; Illa, Isabel (Hospital Universitari Vall d'Hebron) ; Jacob, Saiju (Birmingham Women's and Children's Hospital (Regne Unit)) ; Vissing, John (University of Copenhagen) ; Burns, Ted M. (University of Virginia Health System) ; Kissel, John T. (The Ohio State University) ; Nowak, Richard J. (Yale University) ; Andersen, Henning (Aarhus University Hospital (Aarhus, Dinamarca)) ; Casasnovas, Carlos (Hospital Universitari de Bellvitge) ; De Bleecker, Jan (Universitair Ziekenhuis Gent) ; Vu, Tuan H. (University of South Florida) ; Mantegazza, Renato (Fondazione IRCCS Istituto Neurologico Carlo Besta (R.M.) (Milà, Itàlia)) ; O'Brien, Fanny L. (Alexion Pharmaceuticals) ; Wang, Jing Jing (Alexion Pharmaceuticals) ; Fujita, Kenji P (Alexion Pharmaceuticals) ; Howard, James F. (University of North Carolina)
Introduction : Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. [...]
2019 - 10.1002/mus.26447
Muscle & nerve, Vol. 60 (march 2019) , p. 14-24  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem